The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis ...

Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited ... which one study estimated to account for around 1.4% of autosomal recessive RP cases.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, ...

In February, the Tulsa World is sharing a series of thoughts from Black Tulsans about the future of Tulsa and what role they are playing to make it happen.

Fintel reports that on February 12, 2025, Jones Trading initiated coverage of ProQR Therapeutics N.V. (NasdaqCM:PRQR) with a ...

Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings ...

Premise Health, the largest direct healthcare company serving large employers and unions, and Centivo, the pioneering healthcare company dedicated to making high-quality healthcare more affordable for ...

However, after 4 or more weeks after receiving it ... is being developed for the treatment of patients with X-linked retinitis pigmentosa [XLRP]. Before diving further into this particular ...

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStoptm for the treatment of acid reflux, a treatment field ...

Since his first solo show at the Edinburgh Festival in 1996 saw him nominated for a Perrier Award, Bill has raised uproarious ...

Dr Storey has a price target of $8.40 on the stock against $4.10 currently and $19.65 on ... PYC is looking at therapies across retinitis pigmentosa, polycystic kidney disease, genetic condition ...